Document Classification

Section Type: RESULTS

Text: Atorvastatin treatment compared to placebo resulted in a significant decrease in serum cholesterol (5. 85 + / - 1. 04 mmol/l vs. 4. 22 + / - 0. 69 mmol/l ; mean + / - SD ; P < 0. 001), low-density lipoprotein (LDL) cholesterol (2. 95 + / - 1. 07 mmol/l vs. 1. 82 + / - 0. 92 mmol/l ; P < 0. 001), very low-density lipoprotein (VLDL) cholesterol (0. 31 (0. 21-0. 47) mmol vs. 0. 23 (0. 13-0. 30) mmol/l median (interquartile range) ; P < 0. 05), apolipoprotein B (111 + / - 28 mg/dl vs. 80 + / - 18 mg/dl ; P < 0. 001), and calculated coronary heart disease risk (6. 8 (3. 3-17. 9) vs. 2. 8 (1. 5-5. 7) % over next 10 years ; P < 0. 01).